Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long NVO ETF

12.61
+0.22001.78%
Post-market: 12.610.00000.00%16:10 EDT
Volume:174.01K
Turnover:2.19M
Market Cap:33.01M
PE:- -
High:12.74
Open:12.68
Low:12.40
Close:12.39
52wk High:36.00
52wk Low:9.23
Shares:2.62M
Float Shares:2.62M
Volume Ratio:0.53
T/O Rate:6.65%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study

Simply Wall St.
·
Aug 02

Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?

TIPRANKS
·
Aug 01

Exchange Traded Funds Top 10 Percentage Losers

Dow Jones
·
Aug 01

Nasdaq Composite Index Rises 1% as Amazon Surges 15% After Results; Apple and Micron Fall as Memory Stocks Retreat

TradingKey
·
Aug 01

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

TIPRANKS
·
Aug 01

European Stocks Wipe Out Monthly Gains as Novo Nordisk and Universal Music Plunge

Deep News
·
Aug 01

Canada Net Change Percentage Gainers & Losers

Dow Jones
·
Aug 01

Novo Nordisk A/S Stock (NVO) Moved Down by 8.75% on Jul 31: Key Drivers Unveiled

TradingKey
·
Aug 01

European Equities Mixed in Friday Trading; Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Trial

MT Newswires Live
·
Aug 01

Novo Nordisk A/S Series B Stock Falls Friday, Underperforms Market

Dow Jones
·
Aug 01

Novo Nordisk Falls Over 10% in Largest Single-Day Drop in Nearly Five Months After Announcing Heart Drug Trial Failure

TradingKey
·
Jul 31

Novo Nordisk's Stock Slumps After Failed Trial - Adding to the Company's Woes

Dow Jones
·
Jul 31

Novo Nordisk Heart Drug Trial Failure Triggers Pre-Market Plunge, Deepening Concerns Over Weight Loss Drug Reliance

Stock News
·
Jul 31

Sector Update: Healthcare

MT Newswires Live
·
Jul 31

Novo Nordisk Share Fall Seems Justified by Loss of Big Sales Opportunity

Dow Jones
·
Jul 31

Cardiac Drug Trial Failure Sinks Novo-Nordisk Stock Over 9%

Deep News
·
Jul 31

Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Phase 3 Trial; Shares Fall Pre-Bell

MT Newswires Live
·
Jul 31

Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events Risk in Phase 3 Trial

MT Newswires Live
·
Jul 31

Here Comes the Next Wave of GLP-1s. They'll Treat a Lot More than Obesity.

Dow Jones
·
Jul 31

Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Jul 30